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ABSTRACT
Adenocarcinoma of the endometrium represents the
most common gynecologic malignancy in developed
countries. Although early-stage cancers are effectively
treated surgically, commonly without adjuvant ther-
apy, the treatment of high-risk and advanced disease is
more complex. Chemotherapy has evolved into an im-
portantmodalityinhigh-riskearly-stageandadvanced-
stage disease, and in recurrent endometrial cancer.
Taxane-based therapy consistently demonstrates the
highest response rates in the first-line and salvage set-
tings of endometrial cancer. Unfortunately, response to
chemotherapy is modest and strategies are needed to
predict chemotherapy-responsive and chemotherapy-
resistant populations. Chemotherapy resistance medi-
ated by overexpression of drug efflux pump proteins
and mutations in -tubulin isoforms in both primary
and recurrent disease represent unique treatment chal-
lengesandhighlighttheneedfornewagentsthatareless
susceptibletotheseknownresistancepathways.Epothi-
loneBanalogsarenovelcytotoxicagentswithactivityin
solid tumors, including advanced/recurrent endome-
trial carcinoma, and may have unique properties that
can overcome resistance in some settings. These agents
alone and in combination represent a new therapeutic
opportunity in endometrial carcinoma. The Oncologist
2010;15:1026–1033
AB RIEF OVERVIEW OF
ENDOMETRIAL CARCINOMA
Endometrial carcinoma is the most common gynecologic
malignancy in the U.S. It was estimated that 42,000 new
cases would be diagnosed and 7,700 endometrial carcino-
ma–related deaths would occur in 2009 [1]. This corre-
sponds to a lifetime risk of 2.6% for women living in
developed nations [2], with a median age at diagnosis of
61 years [3]. The epidemiology of endometrial cancer is
multifactorial. Most cases are sporadic and develop in
postmenopausal women. Approximately 2%–5% of endo-
metrialcarcinomasareassociatedwithahereditarygeneal-
teration, nonpolyposis colorectal cancer syndrome, which
isassociatedwithgermlinemutationstoDNAmismatchre-
pair genes [4]. The most common risk factors associated
with the development of endometrial carcinoma are unop-
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Unopposed estrogen replacement therapy and the use of ta-
moxifen are the most common sources of exogenous estro-
gen [6], whereas endogenous sources such as obesity,
cirrhosis,estrogen-producingtumors,andreproductivefac-
tors such as anovulation are also associated with the devel-
opment of endometrial carcinoma [3, 7]. A smaller subset
of sporadic cancers is associated with aging and unique ge-
netic/molecularchanges,producingamoreaggressivevari-
ant, serous/clear cell type (type II cancers).
Most cancers of the endometrium are of endometrioid
histology,followedbytheserousandclearcelltypes[3,8].
In a prospective surgical series of 2,600 patients with
clinically early-stage disease, 78% had endometrioid, 11%
hadserous,and1.6%hadclearcelltumortypes[9].Uterine
sarcomas represent 3%–5% of all uterine cancers. Tumor
stage is determined according to the International Federa-
tion of Gynecology and Obstetrics (FIGO) staging system
and is based on the surgically determined extent of disease
spread. The majority of endometrial cancers are diagnosed
at an early stage, with approximately 72% stage I, 12%
stage II, 13% stage III, and 3% stage IV. FIGO has an-
nounced a revised staging system for 2009 [10]. Whereas
early-stagediseaseisassociatedwithafavorableprognosis,
mortality rates increase with advancing stage of disease
(Table 1) [11].
EVOLUTION OF CHEMOTHERAPY IN THE
MANAGEMENT OF ENDOMETRIAL CANCER
Of all the gynecologic malignancies, the management of
endometrial cancer has undergone the most dramatic shift
in recent years. There has been an introduction and accep-
tanceofminimallyinvasivesurgicaltechniques,morecom-
mon use of surgical staging with pelvic and para-aortic
lymphadenectomy, and greater consideration to remove or
debulk i.p. metastases (akin to ovarian cancer debulking
surgery). A better understanding of uterine factors, includ-
ing tumor grade, depth of invasion, lymph vascular space
invasion, and cervical involvement, and how surgical stag-
ing can define risk strata have altered the use of adjuvant
therapy.Today,thereislessuseofpelvicradiationtherapy,
and when radiation is used a substitution to vaginal cuff
brachytherapy is more common. Most dramatic has been
the introduction of chemotherapy into the first-line man-
agement of patients with high-risk disease. Chemotherapy
was traditionally reserved to treat incurable patients with
disseminated or recurrent endometrial cancer, often after
the failure of hormonal therapy.
Phase II trials have identified doxorubicin, paclitaxel,
and the platinum agents cisplatin and carboplatin as the
most active agents in patients with persistent or recurrent
disease (Table 2) [12]. Two studies demonstrated a higher
response rate (RR) with the combination of cisplatin and
doxorubicin, albeit with a lesser effect on progression-free
survival (PFS) and overall survival (OS) than with single-
agent doxorubicin. The Gynecologic Oncology Group
(GOG) study 107 showed a doubling of the complete RR
(19% versus 8%) and a longer PFS interval (median, 5.7
months versus 3.8 months; hazard ratio [HR], 0.736; confi-
dence interval [CI], 0.577–0.939; p  .014) with the com-
bination[13].TheEuropeanOrganizationforResearchand
Treatment of Cancer similarly showed a higher RR (43%
versus17%)andmodestlybettersurvivalfavoringthecom-
bination [14]. As a result of these studies, the doublet regi-
men became a standard for advancement in many future
phase III studies.
Paclitaxel as a single agent has been evaluated in ad-
vanced/recurrentdiseasepatients,showingRRsof37%(no
prior therapy) and 25% (one prior chemotherapy, 40 of 44
patients treated with doxorubicin–platinum chemother-
apy), making this agent the most active reported in phase II
studies [15, 16]. The GOG subsequently compared doxoru-
bicin–cisplatin with doxorubicin–paclitaxel, and demon-
stratednearlyidenticalRRs,PFSintervals,andOStimesin
Table 1. Endometrial cancer patient survival rate
according to International Federation of Gynecology and
Obstetrics stage
Stage I Stage II Stage III Stage IV
A, 89% A, 80% A, 63% A, 20%
B, 90% B, 72% B, 39% B, 17%
C, 81% C, 51%
Data from Creasman WT, Odicino F, Maisonneuve P
et al. Carcinoma of the corpus uteri. FIGO 6th Annual
Report on the Results of Treatment in Gynecological
Cancer. Int J Gynaecol Obstet 2006;95(suppl 1):
S105–S143.
Table 2. Response rate to single-agent chemotherapy in
chemotherapy-naïve endometrial carcinoma patients
Drug Dose and schedule
Response
rate
Doxorubicin 50–60 mg/m
2 every 3 wks 17%–37%
Paclitaxel 250 mg/m
2 over 24 hours
every 3 wks
36%
Cisplatin 50–100 mg/m
2 every 3 wks 20%–42%
Carboplatin 360–400 mg/m
2 every 4 wks 24%–33%
Data adapted from Fleming GF. Systematic chemotherapy
for uterine carcinoma: Metastatic and adjuvant. J Clin
Oncol 2007;25:2983–2990.
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177 study, a phase III trial comparing doxorubicin–cispla-
tinalonewithdoxorubicin–cisplatinpluspaclitaxel,forthe
first time, a significantly greater RR (57% versus 34%),
PFS interval (median, 8.3 months versus 5.3 months), and
OS time (median, 15.3 months versus 12.3 months) with
combination chemotherapy using the three-drug paclitaxel–
doxorubicin–cisplatin (TAP) regimen were observed [18].
Despite the superior outcomes noted with the three-drug
TAPregimen,neurotoxicityanda3-dayschedulehavelim-
ited enthusiasm for its use. The GOG recently completed a
1,300 patient trial (GOG 209) comparing TAP with pa-
clitaxel–carboplatin in patients with advanced/recurrent
measurable disease or those with advanced disease treated
in an adjuvant setting. The results of the GOG 209 trial,
which completed enrollment in April 2009, are maturing.
In all, the GOG has published four phase III trials in pa-
tients with advanced/recurrent disease including 1,200
patients. RRs of 25%–57%, with the best complete RR of
only 22%, were reported [19]. The population of patients
with advanced or recurrent, measurable disease included in
those trials was relatively heterogeneous and included pa-
tients with stage III, stage IV, and recurrent disease and all
tumor grades and histologic types, and 55% had received
prior radiation therapy. Factors independently associated
with longer survival included white/Hispanic race, better
performance status, stage III disease, no prior radiation
therapy, and endometrioid tumor histology [17].
POSTOPERATIVE CHEMOTHERAPY VERSUS
RADIATION THERAPY
Therehasbeenafundamentalparadigmshifttoincorporate
chemotherapy into the first-line management of patients
with endometrial cancer. In the GOG 122 study, doxoru-
bicin–cisplatin was compared with whole abdominal radi-
ation therapy in patients with small-volume residual stage
III–IV disease [20]. A significantly greater PFS rate (at 60
months, 50% versus 38%) and survival rate (at 60 months,
55% versus 42%) were seen in the chemotherapy arm, with
an HR for death of 0.68 (CI, 0.52–0.89; p  .004). Despite
the improvement associated with chemotherapy, however,
nearly 50% of patients in either arm recurred, showing the
profound need for continued improvement.
Two additional studies compared cyclophosphamide–
cisplatin–doxorubicin (CAP) with pelvic radiation therapy
and demonstrated comparable outcomes in patients with
lessadvanceddisease.InastudyconductedbytheJapanese
GOG, with predominantly early-stage patients (75% stage
I–II), there was no difference between treatment arms in
PFS or OS for all enrolled patients [21]. However, for a
higher risk group IC (stage I with 50% myometrial inva-
sion, with grade 3 tumors or age 70, stage II–IIIa), both
the PFS and OS times were significantly longer in patients
treatedwithchemotherapy.InasimilarstudybyMaggiand
colleagues, with predominantly higher stage patients (62%
stage IIIa/c), no differences in PFS or OS were seen be-
tween patients treated with CAP and those treated with pel-
vic radiation [22]. In both studies, the frequency of disease
recurrence at a distant site with chemotherapy was 16%–
21%, versus 13%–26% with pelvic radiation, indicating
that distant disease control with chemotherapy is perhaps
surprisinglymodest.Atpresent,itisunclearhowtobestde-
fine which patient populations may derive the most benefit
from chemotherapy. Uterine factors (grade, depth of inva-
sion,histology,lymphovascularspaceinvasion)andpatient
age have been used to define risk strata for early-stage pa-
tients,buttheyhavenotbeenusedtopredictwhichpatients
will respond to chemotherapy [23, 24].
CHEMOTHERAPY PLUS RADIATION
Sequential use of chemotherapy and radiation was also
evaluatedintwoprospectivestudies.IntheGOG184study,
patients with stage III disease received volume-directed ra-
diation followed by doxorubicin–cisplatin with or without
paclitaxel.Nodifferenceinthe36-monthPFSratewasseen
between the arms, and distant sites of failure, even with the
use of chemotherapy, were recorded in 28% of patients
[25]. The Norwegian Society of Gynecologic Oncology re-
ported preliminary findings of a randomized trial including
patients at risk for micrometastases (78% stage IB–C),
comparing pelvic radiation alone with pelvic radiation plus
chemotherapy [26]. A variety of chemotherapy regimens
were permitted and chemotherapy could have been admin-
isteredbeforeorafterradiation.The resultsshowedlonger
PFS and cancer-specific survival times favoring the in-
clusion of chemotherapy. Patterns of failure showed that
16% of radiation patients had recurrences outside the ra-
diated field, compared with 10% when chemotherapy
was added. The Radiation Therapy Oncology Group re-
ported a small, phase II trial evaluating concurrent cis-
platin with pelvic radiation followed by four cycles of
paclitaxel–cisplatin chemotherapy in 46 patients with
high-risk disease [27]. That report showed excellent lo-
cal control, with 2% of patients experiencing pelvic fail-
ures, but 19% had a distant recurrence. The trial was the
basis for one of the treatment arms in the ongoing GOG
258 trial (six cycles paclitaxel–carboplatin versus con-
current cisplatin and pelvic radiation followed by four
cycles paclitaxel–carboplatin) in patients with optimally
resected stage III endometrial cancer.
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Although chemotherapy has shown an important role in
high-risk disease, substantial room for improvement exists.
Combination regimens are the most active, but in measur-
able disease populations responses are observed in only
50% or patients, and a complete response is infrequently
observed. Both the PFS and survival times have been im-
proved, yet the 5-year survival rate for patients with ad-
vanced/recurrentmeasurablediseasepatientsis10%,and
for those with stage III disease it is typically around 50%–
60% [19, 20, 22, 25]. After primary therapy with combina-
tion regimens, the efficacy of second-line chemotherapy is
particularly limited (Table 3). Antimicrotubule agents have
shown the most promise. In a population in which 91% had
received doxorubicin–platinum chemotherapy, paclitaxel
producedaRRof25%;theepothiloneBanalogixabepilone
produced an RR of 12% in a population in which 94% had
received prior paclitaxel [16, 28]. Interestingly, docetaxel,
which had shown activity in paclitaxel-treated breast and
ovarian cancer patients, produced an RR of only 8% (80%
had received prior paclitaxel) in patients with advanced/
recurrent endometrial cancer [29]. After failure of primary
chemotherapy, there is no established active second-line
agentinthisdisease.Understandingtheprocessesbywhich
tumors develop resistance is critical, and defining which
patients have the best chance to respond to established or
novel therapies is our greatest challenge.
ENDOMETRIAL CARCINOMA AND
DRUG RESISTANCE
As discussed, combination chemotherapy is increasingly
being used in the first-line treatment of endometrial carci-
noma patients; however, the low initial complete response
rate and the high rate of eventual recurrence or progression
suggest de novo and/or rapidly developing resistance.
Giventheinitialactivityseeninatleastsomepatients,iden-
tifyingwaystotargetcytotoxicagentstotumorsusceptibil-
ityortoavoidagentsthatwillnothaveactivitywouldbean
important advancement. The underlying causes of drug re-
sistance in malignancies are multifactorial. Resistance to
antimicrotubule agents such as paclitaxel is particularly
challenging given the importance of these agents in a vari-
ety of tumor types. Tumor cells in general may develop re-
sistance to paclitaxel by overexpression of the multidrug-
resistance gene (MDR-1), which encodes P-glycoprotein
(P-gp), an efflux pump that prevents accumulation of a va-
riety of natural product–based chemotherapeutic agents
[30, 31]. Point mutations in tubulin-binding sites, where
paclitaxel binds and promotes assembly and stabilization,
have also been identified [32, 33]. Clinically, these two
mechanismsofresistanceseemtobelessrelevant,however
[34].
An additional mechanism of taxane resistance is
through selective overexpression of -tubulin subtypes
such as -tubulin III (-III) and -V [34, 35]. The presence
of -III subunits inhibits the assembly of  subunits pro-
moted by taxanes [36]. In tumor cell lines derived from
lung, ovarian, prostate, and breast cancers, high levels of
-III were associated with taxane resistance [37–39]. This
mechanism may be particularly important because it may
be predictive of taxane response and prognostic for out-
come [34]. In ovarian cancer, high -III expression was as-
sociatedwithashorterPFSdurationandwasindependently
associated with poorer survival [40]. In another report, im-
munohistochemical staining for -III showed higher ex-
pression in histologic types commonly associated with a
poorer response (clear cell, mucinous), and tumors with
high-IIIlevelshadnoresponsetostandardchemotherapy
[41]. Data relating to -III and resistance in endometrial
cancer are limited. However, findings from one study show
that -III expression is common in endometrial cancer and
is not correlated with histologic type or grade, stage, depth
of myometrial infiltration, or lymph node invasion. The au-
thors proposed that this lack of correlation between -III
expression and various histologic features may account for
the relative insensitivity of endometrial cancer to chemo-
therapy [42]. In another study, a -III–expressing aggres-
sive type II endometrial cell line was shown to be resistant
to taxanes, but sensitive to epothilone B. However, down-
regulationof-IIIcorrelatedwithgreatersensitivitytotax-
anes [43]. It has been suggested that drugs such as
epothilone analogs, which selectively target -III tubulin,
may be active in taxane-resistant tumors [34, 44]. To date,
Table 3. Response rate for endometrial carcinoma
patients treated with second-line chemotherapy
Drug Dose and schedule
Response
rate
Cisplatin 50 mg/m
2 every 3 wks 4%
Docetaxel 36 mg/m
2 every wk 7.7%
Pegylated liposomal
doxorubicin
50 mg/m
2 every 4 wks 9.5%
Ixabepilone 40 mg/m
2 every 3 wks 12%
Oxaliplatin 130 mg/m
2 every 3 wks 13.5%
Ifosfamide 1.2 mg/m
2 (5 days)
every 4 wks
15%
Paclitaxel 110–200 mg/m
2 (over 3
hours) every 3 wks
27.3%
Data adapted from Dizon DS, Blessing JA, McMeekin
DS et al. Phase II trial of ixabepilone as second-line
treatment in advanced endometrial cancer: Gynecologic
Oncology Group trial 129-P. J Clin Oncol
2009;27:3104–3108.
1029 Moxley, McMeekin
www.TheOncologist.comno data demonstrating relationships between -III tubulin
expression and outcome have been reported in endometrial
cancer.
In endometrial cancer specifically, other proposed
mechanisms of resistance include inhibition of apoptosis
via alterations in both the extrinsic apoptosis pathway (Fas
proteins) and the intrinsic pathway [inhibitor of apoptosis
proteins (IAP) and Bcl-2], alterations in the phosphatidyl-
inositol 3 kinase (PI3K)–Akt pathway, and p53 mutation
[43, 45–47]. However, no clinical reports validating these
models have been reported. Phase II studies of mammalian
target of rapamycin (mTOR) inhibitors, which have effects
downstream to the PI3K–Akt pathway, appear to hold
promise in endometrial cancer. It is interesting to note that,
in the small series so far conducted, responses appear to be
related by extent of prior therapy with chemotherapy. For
example, in the phase II study of temsirolimus, including a
population of patients who had not been previously treated,
the RR was 26% [48]. Three subsequent trials in patients
who had previously been treated with chemotherapy
showed RRs of 0%–9% using mTOR inhibitors, although
stable disease was common [48–50]. This is somewhat dif-
ferent from what was observed with hormonal therapy, for
which prior exposure to either progestins or chemotherapy
was not thought to alter the other agent’s responsiveness.
To what extent these findings are a result of the different
agents used versus the extent of pretreatment remains to be
explored.
RATIONALE FOR EPOTHILONES IN
ENDOMETRIAL CARCINOMA
The epothilones, a new class of tubulin-polymerization
agents, are macrolide antibiotics obtained from the fermen-
tation of the mycobacterium Sorangium cellulosum. They
were originally recognized by the National Cancer Institute
aspotentcytotoxicagentsin1994,andincludenaturallyoc-
curring epothilones A–F as well as synthetic derivatives
such as ixabepilone [51–53]. The epothilones have a mech-
anism of action similar to that of the taxanes and bind mi-
crotubules near the paclitaxel-binding site, promoting
microtubule stabilization and inducing cell-cycle arrest at
the G2/M checkpoint with subsequent apoptosis. Microtu-
bule inhibitors, such as the taxanes, have demonstrated
efficacyinendometrialcarcinoma;however,thehydropho-
bic nature of paclitaxel makes it highly susceptible to the
multidrug resistance protein (MRP), which facilitates cel-
lular efflux of the drug and limits cytotoxicity. Unlike the
taxanes, epothilones and their synthetic derivatives demon-
strate potent activity in multidrug-resistant cell lines. Not
only are these agents able to overcome drug resistance, but
they do not readily induce the overexpression of MRP-1 or
P-gp resistance mechanisms in epithelial tumor cells
[54, 55].
Ixabepilone, a semisynthetic lactam derivative of
epothilone B, is a metabolically stable form of this agent.
Ixabepilone has demonstrated preclinical efficacy across a
broad range of cancer models with 50 inhibitory concentra-
tions in the low nanomolar range. Importantly, preclinical
data have demonstrated significant antitumor activity in
clinically derived paclitaxel-resistant carcinomatous cell
lines [56]. Synergistic antitumor activity was demonstrated
in vivo when ixabepilone was used in conjunction with
commonly used cytotoxic and biologic agents such as cis-
platin, capecitabine, bevacizumab, sunitinib, cetuximab,
and trastuzumab [55, 57, 58]. Preclinical data have also
demonstrated that ixabepilone has antitumor activity in pa-
clitaxel-resistant cell lines overexpressing -III. Given
these findings, the development of ixabepilone advanced
into clinical studies as a potential treatment in patients with
heavily pretreated or chemotherapy-resistant malignancies
[55].
Phase II and phase III clinical trials demonstrated the
antitumor activity of ixabepilone in solid tumors of the
ovary, uterine cervix, pancreas, breast, and lung (non-small
cell), as well as in non-Hodgkin’s lymphoma [56]. Recent
findings from a phase II trial of ixabepilone in patients with
recurrentorpersistentplatinum-ortaxane-resistantovarian
or peritoneal cancer showed a response rate of 14.3% and
an acceptable safety profile [59]. Ixabepilone as a single
agent is approved for use in breast cancer that has pro-
gressed following therapy with a taxane, an anthracycline,
and capecitabine, and in combination with capecitabine in
patientswithmetastaticorlocallyadvanceddiseasethathas
progressed after taxane and anthracycline therapy. Dose-
limiting toxicities consist of neutropenia, peripheral neu-
ropathy,andfatigue,whicharelowerwitha3-hourinfusion
of 40 mg/m
2. Other toxicities include hypersensitivity re-
quiring premedication, myalgia, arthralgia, alopecia, nau-
sea/vomiting, anorexia, and stomatitis, with a safety profile
that is similar across trials in a variety of solid tumors [54].
THE FUTURE OF THE EPOTHILONES IN
ENDOMETRIAL CARCINOMA
Given the propensity of endometrial carcinomas to possess
inherent resistance to current cytotoxic agents or develop
broadresistancefollowingfirst-linetherapy,epothilonean-
alogs such as ixabepilone should be further evaluated. Par-
ticularly exciting are the demonstrated properties in vitro,
showing activity against multidrug-resistant metastatic
breast cancer, and in clinical practice, showing activity
against taxane-resistant breast and endometrial cancers. At
the present time, translational and clinical data are lacking
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pression. An ongoing phase III trial in recurrent/persistent
endometrial carcinoma patients previously treated with
chemotherapy (Clinical Protocol CA136196) is comparing
ixabepilone with paclitaxel or doxorubicin and includes the
collection of pathologic materials for translational research
to validate the hypothesis that ixabepilone may have a
uniquerolein-III–expressingtumors.Interestingly,aret-
rospective analysis of data from a clinical trial of neoadju-
vant ixabepilone showed that patients with triple-negative
breast cancer had higher -III expression levels, and sug-
gested that -III expression may predict response to ixa-
bepilone [60].
Whereas single-agent ixabepilone therapy has demon-
stratedactivityinresistantsolidtumorsinvivoandinvitro,
synergistic antitumor activity was also demonstrated in
vivo with the combination of ixabepilone and bevaci-
zumab. Cell models derived from breast, colon, lung, and
kidney carcinomas have been evaluated and clinical trials
are now being conducted to assess this specific drug com-
bination. Initial data from a randomized, phase II study of
ixabepilone and bevacizumab for the first-line treatment of
metastatic breast cancer have shown encouraging clinical
activityandasafetyprofilesimilartothatofbevacizumab–
paclitaxel [61]. Based on promising results supporting
combination regimens with cytotoxic and targeted agents,
the GOG recently opened a randomized phase II clinical
trial using these agents in combination. This three-armed
trial is randomizing stage III/IV patients at primary diagno-
sis and patients with disease recurrence who have received
no prior chemotherapy to receive either paclitaxel–carbo-
platin–bevacizumab or paclitaxel–carboplatin–temsiroli-
mus or ixabepilone–carboplatin–bevacizumab every 21
days. That trial is early in patient accrual, but is representa-
tiveofthecurrenttreatmentstrategiesusingepothilonesfor
endometrial carcinomas.
SUMMARY
Advanced and recurrent endometrial carcinomas remain a
challenging group of tumors that are only modestly respon-
sive to first-line chemotherapy and demonstrate high rates
of multifactorial chemotherapy resistance. Ixabepilone and
the other epothilones offer better efficacy against such tu-
mors because of their lesser susceptibility to known tumor
resistance mechanisms, such as drug efflux pumps and
-tubulin mutations. The rationale for using epothilones
aloneandincombinationinpatientswiththishigh-riskma-
lignancy is scientifically sound and warrants future explo-
ration.
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